Condition: Ulcerative Colitis (UC) · Inflammatory Bowel Disease (IBD) · Fibroblast Activation Protein Inhibitor · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging
This description comes directly from the study's public registry record.
Dalia A Lartey, MD · +31205668160 · d.a.lartey@amsterdamumc.nl
Kelly van Wijnbergen, Msc · +31205668160 · k.vanwijnbergen@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Amsterdam UMC | Amsterdam, North Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06604273